Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II)
A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis
Existing samples:
- Malignant tumor of lung (disorder)
Bespoke collection capabilities:
- Malignant tumor of lung (disorder)
Contact Information
- Email:
- ctc.darwin2@ucl.ac.uk
- Address:
-
CRUK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
Greater London
W1T 4TJ
England
Last Updated: 10/19/2018
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |